Up­dat­ed: No­var­tis dis­con­tin­ues lead Gy­ro­scope gene ther­a­py af­ter $800M+ buy­out

No­var­tis is pulling the plug on the lead gene ther­a­py pro­gram from a biotech it paid $800 mil­lion up­front to ac­quire, as the Big Phar­ma con­tin­ues to re­or­ga­nize its pipeline.

No­var­tis said Mon­day that GT005, a gene ther­a­py de­vel­oped by Gy­ro­scope Ther­a­peu­tics for ge­o­graph­ic at­ro­phy for pa­tients with dry age-re­lat­ed AMD, is be­ing dis­con­tin­ued af­ter a Phase II tri­al did not pass muster with an in­de­pen­dent da­ta mon­i­tor­ing com­mit­tee.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER